The last several weeks have been good times for tech sector investors as the Nasdaq Composite Index has risen to a new all-time high. Yet, as I’ll explain here, the tech sector’s strong appearance belies an Achilles heel which will eventually slow the market’s rate of ascent.
In this report, we’ll discuss the continued and persistent weakness within the healthcare sector – specifically the pharmaceutical and biotech stocks. I’ll present the case that the liquidation underway in this market segment will act as a check on the Nasdaq’s recent progress. What’s more, until the U.S.-China